Cost-effectiveness of biomarker-directed toripalimab plus chemotherapy for previously untreated extensive-stage small-cell lung-cancer in China
Sign Up to like & getrecommendations! Published in 2025 at "PLOS One"
DOI: 10.1371/journal.pone.0328730
Abstract: Background With or without biomarker-directed toripalimab plus chemotherapy could bring significant clinical benefit and acceptable safety profile compared with chemotherapy as first-line treatment for patients with extensive-stage small-cell lung-cancer (ES-SCLC) were demonstrated in EXTENTORCH trial.… read more here.
Keywords: plus chemotherapy; toripalimab plus; directed toripalimab; cost ... See more keywords